Its results will be poised to guide future wide-scale implementation—both within and outside of large healthcare systems—of cascade screening for FH and other autosomal dominant genetic conditions, such as hypertrophic cardiomyopathies, arrhythmic disorders, Lynch syndrome, and gene mutations implicated in cancer risks such as BRCA1 and BRCA2. This evidence concerns the gene BRCA1 and familial hyperaldosteronism.